New
Emerging drugs for the treatment of vitiligo
Our co-authored paper titled Emerging drugs for the treatment of vitiligo has been published in the journal Expert Opinion on Emerging Drugs.
This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant and repigmenting mechanisms, basic fibroblast growth factors, afamelanotide and targeted immunotherapy.
For more information about emerging treatments for vitiligo, check out Drug Pipelines or Trials Hub sections of our website.
We also recommend reading our exclusive Vitiligo Drug Pipeline Analysis and Market Insights.
FAQOther Questions
- What's better: laser or phototherapy?
Laser therapy is actually a type of phototherapy. Both rely on light to trigger changes in the skin, but they work differently. Phototherapy usually means a narrow-band UV (NB-U...
- What causes vitiligo?
The exact cause is a complex puzzle, but we know the foundation: It is pre-wired in your genes. Think of your genetics as a loaded spring, just waiting for a specific "trigger" ...
- Which diseases most commonly accompany vitiligo?
Vitiligo is rarely an isolated event. Because it involves an overactive immune system, it often coexists with other autoimmune disorders. According to extensive 10-year clinical...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.